BRAF突变对甲状腺乳头状癌摄碘相关蛋白表达影响及相关分子靶向治疗  

Recent advances in molecular targeted therapy and expression of iodine uptake relative protein in papillary thyroid carcinoma with BRAFv mutation

作　　者：杜秋丽[1] 黄韬[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院乳腺甲状腺外科,武汉430022

出　　处：《中华内分泌代谢杂志》2013年第7期624-626,共3页Chinese Journal of Endocrinology and Metabolism

摘　　要：B型RAF基因（BRAF）是近年来甲状腺癌中研究最热的基因之一，其突变与甲状腺乳头状癌的发生发展及治疗、预后有着重要的联系，本文就BRAF。突变对乳头状甲状腺癌细胞中摄碘相关蛋白碘钠同向转运体、促甲状腺激素受体表达的影响及其相关的分子靶向治疗进行综述，并对其在乳头状甲状腺癌治疗中的临床价值进行评述、展望。Type-B RAF （BRAF） gene is one of the most popular genes of thyroid carcinoma in recent studies, and its mutation has significant relationships with the occurrence, development, treatment, and prognosis of papillary thyroid carcinoma（ PTC ）. The influence of BRAFmutation on the expression of iodine uptake relative proteins in PTC cells and the value of molecular targeted therapy with BRAF Einhibitors in the clinical treatment of PTC in the future were summarized in this review.

关 键 词：BRAF 甲状腺乳头状癌 钠碘同向转运体 促甲状腺激素受体 分子靶向治疗 

分 类 号：R736.1[医药卫生—肿瘤]